Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.13 USD

96.13
436,930

+1.70 (1.80%)

Updated May 20, 2024 04:00 PM ET

After-Market: $96.14 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 249)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Grow

Amedisys (AMED) reports better-than-expected earnings for the second quarter with strong performance in Home Health and Hospice segments.

Amedisys (AMED) Beats Q2 Earnings Estimates

Amedisys (AMED) delivered earnings and revenue surprises of 3.05% and -0.09%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Amedisys (AMED) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EHC or AMED: Which Is the Better Value Stock Right Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

3 Reasons to Add LHC Group (LHCG) Stock to Your Portfolio

Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of deals and a broad array of services.

Amedisys (AMED) Latest New York Assets Buyout Aids Home Health

The latest development remains in line with Amedisys' (AMED) ongoing efforts to expand footprint in key markets.

EHC or AMED: Which Is the Better Value Stock Right Now?

EHC vs. AMED: Which Stock Is the Better Value Option?

Amedisys' (AMED) VNA Assets Buyout Boosts Home Health-Hospice

Leveraging on VNA's home health and hospice care legacy, Amedisys (AMED) expects to provide additional scale and resources.

Encompass Health (EHC) to Expand Inpatient Rehabilitation Unit

Encompass Health (EHC) to construct an inpatient rehabilitation hospital to capture a market with great prospects.

Amedisys (AMED) Soars 6.7%: Is Further Upside Left in the Stock?

Amedisys (AMED) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Amedisys' (AMED) Contessa Buyout to Boost Home Health Business

Amedisys (AMED) inks deal to acquire Contessa Health to boost home health and hospice services business.

DVA or AMED: Which Is the Better Value Stock Right Now?

DVA vs. AMED: Which Stock Is the Better Value Option?

5 Reasons That Make Encompass Health (EHC) an Attractive Bet

Encompass Health's (EHC) optimistic business prospects make it a lucrative stock to own for strong gains.

Encompass Health (EHC) Expands Inpatient Rehab Business

Encompass Health (EHC) continues to strengthen its inpatient rehabilitation business by opening a hospital.

Accuray (ARAY) Expands Commercialization of CE-Marked ClearRT

Accuray's (ARAY) ClearRT imaging capability, which is now widely available following receipt of the CE Mark, offers better precision and accuracy in radiation therapy.

Here's Why You Should Retain LHC Group (LHCG) Stock for Now

Investors continue to be optimistic about LHC Group (LHCG) owing to its slew of buyouts and a broad array of services.

Baxter's (BAX) Theranova-Enabled HDx Therapy Data Positive

Baxter's (BAX) Theranova-enabled HDx therapy is likely to boost clinical outcomes and lower healthcare resource utilization.

Why You Should Add Veeva Systems (VEEV) to Your Portfolio

Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.

Syneos' (SYNH) New Patient Consortium to Drive Innovation

Syneos' (SYNH) Patient Voice Consortium incorporates patient perspective across wide range of communities to guide product development lifecycle.

DVA vs. AMED: Which Stock Is the Better Value Option?

DVA vs. AMED: Which Stock Is the Better Value Option?

Here's Why You Should Retain PRA Health (PRAH) Stock for Now

Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.

Cooper Companies (COO) Unit's Ortho-K Lens Receives CE Mark

Cooper Companies' (COO) unit CooperVision's latest orthokeratology contact lens becomes the latest myopia control product to gain European approval.

Here's Why You Should Retain PerkinElmer (PKI) Stock Now

PerkinElmer (PKI) continues to gain traction on a solid product portfolio and improving margins. However, forex woes linger.

BD (BDX) to Boost Lab Efficacy With BD Kiestra UCA's U.S. Launch

BD's (BDX) UCA leverages AI to revolutionize the way microbiology labs conduct urine culture analysis.

Cooper Companies (COO) to Post Q2 Earnings: What's in Store?

Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.